Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET....
Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Orbassano, Turin, Italy giorgio.scagliotti@unito.it.
G V
GV
Scagliotti
Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
M
M
Di Maio
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*
C551661:ARQ 197; D000970:Antineoplastic Agents; D011760:Pyrrolidinones; D011804:Quinolines; D000069347:Erlotinib Hydrochloride; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met